uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.492 | Q17 | What gene does the drug Onasemnogene Abeparvovec target? | The drug Onasemnogene Abeparvovec targets 2 genes: SMN1 and SMN2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onasemnogene abeparvovec%" OR LOWER(tradeNames_string) LIKE "%onasemnogene abeparvovec%" OR LOWER(drugSynonyms_string) LIKE "%onasemnogene abeparvovec%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3439', 'drugName': 'Onasemnogene Abeparvovec', 'tradeNames_string': '', 'drugSynonyms_string': 'AVXS-101, Onasemnogene abeparvovec, Zolgensma', 'linkedDiseasesDrug_string': 'Spinal Muscular Atrophy (EFO_0008525)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMN1 (ENSG00000172062), SMN2 (ENSG00000205571)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.445 | Q17 | What gene does the drug Cyclofenil target? | The drug Cyclofenil targets 2 genes: ESR2 and ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cyclofenil%" OR LOWER(tradeNames_string) LIKE "%cyclofenil%" OR LOWER(drugSynonyms_string) LIKE "%cyclofenil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1475', 'drugName': 'Cyclofenil', 'tradeNames_string': 'Neoclym, Rehibin', 'drugSynonyms_string': 'Cyclofenil, F 6066, F-6066, ICI 48213, ICI-48213, NSC-86464, Sexovid', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.274 | Q17 | What gene does the drug Capadenoson target? | The drug Capadenoson is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADORA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%capadenoson%" OR LOWER(tradeNames_string) LIKE "%capadenoson%" OR LOWER(drugSynonyms_string) LIKE "%capadenoson%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3660', 'drugName': 'Capadenoson', 'tradeNames_string': '', 'drugSynonyms_string': 'BAY 68-4986, BAY-68-4986, Bay-684986, Capadenoson', 'linkedDiseasesDrug_string': 'Angina Pectoris (EFO_0003913), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.187 | Q17 | What gene does the drug Mirdametinib target? | The drug Mirdametinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MAP2K2 and MAP2K1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mirdametinib%" OR LOWER(tradeNames_string) LIKE "%mirdametinib%" OR LOWER(drugSynonyms_string) LIKE "%mirdametinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_179', 'drugName': 'Mirdametinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Mirdametinib, PD-0325901, Pd 0325901, Pd 03525901, Pd 901, Pd-0325901', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Neurofibromatosis Type 1 (MONDO_0018975), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_180', 'drugName': 'Mirdametinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Mirdametinib, PD-0325901, Pd 0325901, Pd 03525901, Pd 901, Pd-0325901', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Neurofibromatosis Type 1 (MONDO_0018975), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.950 | Q17 | What gene does the drug Tarenflurbil target? | The drug Tarenflurbil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: APH1A, APH1B, PSEN1, PSENEN, NCSTN and PSEN2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tarenflurbil%" OR LOWER(tradeNames_string) LIKE "%tarenflurbil%" OR LOWER(drugSynonyms_string) LIKE "%tarenflurbil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2667', 'drugName': 'Tarenflurbil', 'tradeNames_string': 'Flurizan', 'drugSynonyms_string': 'E-7869, Flurbiprofen, (r)-, MPC-7869, R-flurbiprofen, Tarenflurbil', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Prostate Cancer (MONDO_0008315), Dementia (HP_0000726)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'APH1A (ENSG00000117362), PSENEN (ENSG00000205155), APH1B (ENSG00000138613), PSEN1 (ENSG00000080815), NCSTN (ENSG00000162736), PSEN2 (ENSG00000143801)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.247 | Q17 | What gene does the drug Prazosin Hydrochloride target? | The drug Prazosin Hydrochloride targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prazosin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%prazosin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%prazosin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5265', 'drugName': 'Prazosin Hydrochloride', 'tradeNames_string': 'Alphavase 0.5, Alphavase 1, Alphavase 2, Alphavase 5, Hypovase, Hypovase b.d., Kentovace, Minipress, Minipress xl, Prazosin hydrochloride', 'drugSynonyms_string': 'CP-12,299-1, CP-12299-1, NSC-292810, Prazosin hcl, Prazosin hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1100 | Q17 | What gene does the drug Lerodalcibep target? | The drug Lerodalcibep is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PCSK9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lerodalcibep%" OR LOWER(tradeNames_string) LIKE "%lerodalcibep%" OR LOWER(drugSynonyms_string) LIKE "%lerodalcibep%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6016', 'drugName': 'Lerodalcibep', 'tradeNames_string': '', 'drugSynonyms_string': 'Lerodalcibep', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Homozygous Familial Hypercholesterolemia (MONDO_0018328), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1018 | Q17 | What gene does the drug Aclidinium Bromide target? | The drug Aclidinium Bromide targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aclidinium bromide%" OR LOWER(tradeNames_string) LIKE "%aclidinium bromide%" OR LOWER(drugSynonyms_string) LIKE "%aclidinium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6136', 'drugName': 'Aclidinium Bromide', 'tradeNames_string': 'Eklira, Tudorza pressair', 'drugSynonyms_string': '14115700, Aclidinium bromide, Genuair, LAS 34273, LAS 34273 MICRONIZED, LAS W-330, LAS-34273, LAS-34273 MICRONIZED, LAS-W-330', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Nicotine Dependence (EFO_0003768), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.590 | Q17 | What gene does the drug Benzthiazide target? | The drug Benzthiazide targets the gene SLC12A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzthiazide%" OR LOWER(tradeNames_string) LIKE "%benzthiazide%" OR LOWER(drugSynonyms_string) LIKE "%benzthiazide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2994', 'drugName': 'Benzthiazide', 'tradeNames_string': 'Aquatag, Benzthiazide, Exna, Fovane, Urese', 'drugSynonyms_string': 'Benzothiazide, Benzthiazide, NSC-755902', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A3 (ENSG00000070915)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1629 | Q17 | What gene does the drug Gemfibrozil target? | The drug Gemfibrozil targets the gene PPARA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gemfibrozil%" OR LOWER(tradeNames_string) LIKE "%gemfibrozil%" OR LOWER(drugSynonyms_string) LIKE "%gemfibrozil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6015', 'drugName': 'Gemfibrozil', 'tradeNames_string': 'Emfib, Gemfibrozil, Lopid', 'drugSynonyms_string': 'CI-719, Gemfibrozil, NSC-757024', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Smoking Cessation (EFO_0004319), Hypertriglyceridemia (EFO_0004211), Hiv Infection (EFO_0000764), Coronary Artery Disease (EFO_0001645), Nicotine Dependence (EFO_0003768), Anemia (Phenotype) (EFO_0004272), Cardiovascular Disease (EFO_0000319), Abdominal Pain (HP_0002027), Type 2 Diabetes Mellitus (MONDO_0005148), Alcohol Dependence (MONDO_0007079), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.535 | Q17 | What gene does the drug Norgestrel target? | The drug Norgestrel targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norgestrel%" OR LOWER(tradeNames_string) LIKE "%norgestrel%" OR LOWER(drugSynonyms_string) LIKE "%norgestrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6188', 'drugName': 'Norgestrel', 'tradeNames_string': 'Opill, Ovrette', 'drugSynonyms_string': 'Dl-norgestrel, FH-122A, NSC-757251, Norgestrel, Prefest, Previfem, SH-70850, SH-850, Sprintec, Tri-Previfem, Tri-Sprintec, WY-3707', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914), Endometrial Cancer (MONDO_0011962)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2857', 'drugName': 'Levonorgestrel', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugSynonyms_string': 'BAY86-5028, Levonorgestrel, Levonorgestrelum, NSC-744007, Norgestrel (-)-form, Norgestrel, (-)-, WY-5104', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4354', 'drugName': 'Norgestimate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexnorgestrel acetime, NSC-759159, Norgestimate, ORF 10131, ORF-10131, RWJ 10131, RWJ-10131', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hiv Infection (EFO_0000764), Migraine Disorder (MONDO_0005277), Metrorrhagia (HP_0100608), Neural Tube Defect (MONDO_0018075), Cystic Fibrosis (MONDO_0009061), Acne (EFO_0003894), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.899 | Q17 | What gene does the drug Loperamide Hydrochloride target? | The drug Loperamide Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loperamide hydrochloride%" OR LOWER(tradeNames_string) LIKE "%loperamide hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%loperamide hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6052', 'drugName': 'Loperamide Hydrochloride', 'tradeNames_string': 'Arret, Diah-limit, Diaquitte, Diareze, Diarrhoea relief, Diasorb, Diocalm, Diocaps, Dioraleze, Entrocalm, Gppe pack, Imodium, Imodium Advanced, Imodium a-d, Imodium a-d ez chews, Imodium classic, Imodium ibs relief, Imodium instant melts, Imodium instants, Imodium liquicaps, Lodiar, Loperagen, Loperamide hydrochloride, Norimode, Normaloe', 'drugSynonyms_string': 'Loperamide hcl, Loperamide hydrochloride, Loperamidi hydrochloridum, NSC-696356, R 18,553, R-18553', 'linkedDiseasesDrug_string': 'Diarrhea (HP_0002014)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1483 | Q17 | What gene does the drug Ono-2333Ms target? | The drug Ono-2333Ms is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CRHR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ono-2333ms%" OR LOWER(tradeNames_string) LIKE "%ono-2333ms%" OR LOWER(drugSynonyms_string) LIKE "%ono-2333ms%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2958', 'drugName': 'Ono-2333Ms', 'tradeNames_string': '', 'drugSynonyms_string': 'Ono-2333ms', 'linkedDiseasesDrug_string': 'Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CRHR1 (ENSG00000120088)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1109 | Q17 | What gene does the drug Dorzolamide target? | The drug Dorzolamide targets the gene CA2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dorzolamide%" OR LOWER(tradeNames_string) LIKE "%dorzolamide%" OR LOWER(drugSynonyms_string) LIKE "%dorzolamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_333', 'drugName': 'Dorzolamide', 'tradeNames_string': 'Dorzant, Trusopt', 'drugSynonyms_string': 'Dorzolamide, Dorzolamide, trans-(-)-, MK-507, Trusopt', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Wet Macular Degeneration (EFO_0004683), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1719', 'drugName': 'Dorzolamide Hydrochloride', 'tradeNames_string': 'Cosopt Pf, Dorzolamide hydrochloride, Trusopt', 'drugSynonyms_string': 'Dorzolamide (as hydrochloride), Dorzolamide hcl, Dorzolamide hydrochloride, MK-507', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.421 | Q17 | What gene does the drug Ranitidine target? | The drug Ranitidine targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ranitidine%" OR LOWER(tradeNames_string) LIKE "%ranitidine%" OR LOWER(drugSynonyms_string) LIKE "%ranitidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1617', 'drugName': 'Ranitidine Hydrochloride', 'tradeNames_string': 'Azantac, Dumoran, Gavilast, Gavilast-p, Histac, Raciran 150, Raciran 300, Ranicalm, Raniplex, Ranitic, Ranitidine hydrochloride, Ranitil, Rantec, Ranzac, Vivatak, Zaedoc 150, Zaedoc 300, Zantac, Zantac 150, Zantac 25, Zantac 300, Zantac 75, Zantac 75 dissolve, Zantac 75 relief, Zantac 75 relief dissolve', 'drugSynonyms_string': 'AH 19065, AH-19065, Ranitidine hcl, Ranitidine hydrochloride, Taladine', 'linkedDiseasesDrug_string': 'Ulcer Disease (MONDO_0043839), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4211', 'drugName': 'Ranitidine', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-757851, Ranitidine, Tritec, Zantac', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Cough (HP_0012735), Breast Carcinoma In Situ (MONDO_0004658), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Ulcer Disease (MONDO_0043839), Peptic Ulcer (HP_0004398), Immune System Disease (EFO_0000540), Renal Cell Carcinoma (EFO_0000681), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Postpartum Hemorrhage (EFO_0009579), Gastroesophageal Reflux Disease (EFO_0003948), T-Lymphoblastic Lymphoma (MONDO_0044917), Hiv Infection (EFO_0000764), T-Cell Leukemia (EFO_0005592), Autosomal Dominant Hyper-Ige Syndrome (Orphanet_2314), Helicobacter Pylori Infectious Disease (EFO_1000961), Barrett'S Esophagus (EFO_0000280)", 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4141', 'drugName': 'Ranitidine Bismuth Citrate', 'tradeNames_string': 'Pylorid, Tritec', 'drugSynonyms_string': 'GR 122311X, GR-122311X, Ranitidine bismuth citrate, Ranitidine bismutrex', 'linkedDiseasesDrug_string': 'Peptic Ulcer (HP_0004398), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.277 | Q17 | What gene does the drug Doxepin target? | The drug Doxepin targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxepin%" OR LOWER(tradeNames_string) LIKE "%doxepin%" OR LOWER(drugSynonyms_string) LIKE "%doxepin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2495', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_string': 'Adapin, Doxepin hydrochloride, Quitaxon, Silenor, Sinequan, Xepin, Zonalon', 'drugSynonyms_string': 'Doxepin hcl, Doxepin hydrochloride, NSC-108160, P-3693A', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pain (EFO_0003843), Atopic Eczema (EFO_0000274), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Oral Mucositis (EFO_1001904), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1761', 'drugName': 'Doxepin', 'tradeNames_string': 'Sinepin, Sinequan', 'drugSynonyms_string': 'Doxepin, P-3693A, Zonalon', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Sleep Disorder (EFO_0008568), Breast Cancer (MONDO_0007254), Pain (EFO_0003843), Urticaria (EFO_0005531), Atopic Eczema (EFO_0000274), Dementia (HP_0000726), Anxiety (EFO_0005230), Irritable Bowel Syndrome (EFO_0000555), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Depressive Disorder (MONDO_0002050), Oral Mucositis (EFO_1001904), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1174 | Q17 | What gene does the drug Obeticholic Acid target? | The drug Obeticholic Acid targets the gene NR1H4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%obeticholic acid%" OR LOWER(tradeNames_string) LIKE "%obeticholic acid%" OR LOWER(drugSynonyms_string) LIKE "%obeticholic acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3863', 'drugName': 'Obeticholic Acid', 'tradeNames_string': 'Ocaliva', 'drugSynonyms_string': '6-ecdca, 6-ethylchenodeoxycholic acid, DSP-1747, INT-747, Obeticholic acid', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Hepatitis, Alcoholic (EFO_1001345), Diarrhea (HP_0002014), Cholangitis (HP_0030151), Liver Disease (EFO_0001421), Biliary Liver Cirrhosis (EFO_0004267), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Cholestasis (MONDO_0001751), Barrett'S Esophagus (EFO_0000280), Sclerosing Cholangitis (EFO_0004268), Pruritus (HP_0000989), Primary Biliary Cirrhosis (EFO_1001486), Familial Partial Lipodystrophy (MONDO_0020088)", 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR1H4 (ENSG00000012504)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1487 | Q17 | What gene does the drug Balsalazide target? | The drug Balsalazide targets 4 genes: PTGS2, PPARG, ALOX5 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%balsalazide%" OR LOWER(tradeNames_string) LIKE "%balsalazide%" OR LOWER(drugSynonyms_string) LIKE "%balsalazide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1298', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1078', 'drugName': 'Balsalazide', 'tradeNames_string': '', 'drugSynonyms_string': 'Balsalazide', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1077', 'drugName': 'Balsalazide', 'tradeNames_string': '', 'drugSynonyms_string': 'Balsalazide', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1296', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1297', 'drugName': 'Balsalazide Disodium', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugSynonyms_string': 'BX-661A, BX661A, Balsalazide disodium, Balsalazide disodium anhydrous, Balsalazide disodium dihydrate, Balsalazide disodium salt dihydrate, Balsalazide sodium, Balsalazine, NSC-760046', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1079', 'drugName': 'Balsalazide', 'tradeNames_string': '', 'drugSynonyms_string': 'Balsalazide', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1456 | Q17 | What gene does the drug Milciclib target? | The drug Milciclib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: NTRK1, CDK4, CDK2 and CDK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%milciclib%" OR LOWER(tradeNames_string) LIKE "%milciclib%" OR LOWER(drugSynonyms_string) LIKE "%milciclib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5842', 'drugName': 'Milciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'Milciclib, PHA 848125, PHA-848125, Pha-848125', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Hepatocellular Carcinoma (EFO_0000182), Thymic Carcinoma (EFO_1000576), Thymoma (EFO_1000581)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5841', 'drugName': 'Milciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'Milciclib, PHA 848125, PHA-848125, Pha-848125', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Hepatocellular Carcinoma (EFO_0000182), Thymic Carcinoma (EFO_1000576), Thymoma (EFO_1000581)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5844', 'drugName': 'Milciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'Milciclib, PHA 848125, PHA-848125, Pha-848125', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Hepatocellular Carcinoma (EFO_0000182), Thymic Carcinoma (EFO_1000576), Thymoma (EFO_1000581)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5843', 'drugName': 'Milciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'Milciclib, PHA 848125, PHA-848125, Pha-848125', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Hepatocellular Carcinoma (EFO_0000182), Thymic Carcinoma (EFO_1000576), Thymoma (EFO_1000581)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.253 | Q17 | What gene does the drug Terfenadine target? | The drug Terfenadine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%terfenadine%" OR LOWER(tradeNames_string) LIKE "%terfenadine%" OR LOWER(drugSynonyms_string) LIKE "%terfenadine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2637', 'drugName': 'Terfenadine', 'tradeNames_string': 'Antihistamine, Histafen, Histafen 120, Seldane, Terfenor, Terfenor fte, Terfex, Terfinax 120, Terfinax 60, Triludan, Triludan fte', 'drugSynonyms_string': 'NSC-665802, NSC-758627, RMI 9918, RMI-9918, Terfenadine', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Asthma (MONDO_0004979), Hepatitis B Virus Infection (EFO_0004197), Multiple Sclerosis (MONDO_0005301), Hepatitis D Virus Infection (EFO_0007304), Chronic Progressive Multiple Sclerosis (EFO_0003840), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Disease (MONDO_0005271), Peanut Allergic Reaction (EFO_0007425)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.419 | Q17 | What gene does the drug Prednisone target? | The drug Prednisone targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_string) LIKE "%prednisone%" OR LOWER(drugSynonyms_string) LIKE "%prednisone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2255', 'drugName': 'Prednisone', 'tradeNames_string': 'Cortan, Cortancyl, Decortisyl, Delta-dome, Deltasone, Fernisone, Liquid pred, Lodotra, Meticorten, Orasone, Paracort, Prednicen-m, Prednisone, Prednisone intensol, Rayos, Servisone, Sterapred', 'drugSynonyms_string': '3en3hg4wsw, Decortin, Dehydrocortisone, Metacortandracin, NSC-10023, Prednisone, Prednisone anhydrous, Prednisone tablets, Supercortil', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Essential Thrombocythemia (EFO_0000479), Lymphoplasmacytic Lymphoma (MONDO_0000432), Hemophagocytic Syndrome (MONDO_0015540), Vasculitis (EFO_0006803), Iga Glomerulonephritis (EFO_0004194), Igg4-Related Retroperitoneal Fibrosis (MONDO_0018848), Allergic Rhinitis (EFO_0005854), Lung Disease (EFO_0003818), Iridocyclitis (HP_0001094), Eosinophilic Pneumonia (EFO_0007257), Temporal Arteritis (EFO_1001209), Graves Ophthalmopathy (EFO_1001466), Sciatica (HP_0011868), Pemphigus Vulgaris (EFO_0004719), Seasonal Allergic Rhinitis (EFO_0003956), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hearing Loss (EFO_0004238), Hypereosinophilic Syndrome (EFO_1001467), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Keratitis (EFO_0009449), Nasal Cavity Polyp (EFO_1000391), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Viral Pneumonia (EFO_0007541), Hemangioma (EFO_1000635), Castleman Disease (MONDO_0015564), Hemolytic Anemia (EFO_0005558), Thymus Neoplasm (EFO_0002626), T-Lymphoblastic Lymphoma (MONDO_0044917), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Iritis (EFO_1000997), Heart Disease (EFO_0003777), Follicular Lymphoma (MONDO_0018906), Chronic Inflammatory Demyelinating Polyneuropathy (EFO_0009538), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Churg-Strauss Syndrome (EFO_0007208), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Autoimmune Hepatitis (EFO_0005676), Takayasu Arteritis (EFO_1001857), Adrenocortical Insufficiency (EFO_0009491), Kidney Disease (EFO_0003086), Myocarditis (EFO_0009609), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Stevens-Johnson Syndrome (EFO_0004276), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Opsoclonus-Myoclonus Syndrome (EFO_1001383), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Juvenile Dermatomyositis (EFO_0000557), Pain (EFO_0003843), Sympathetic Ophthalmia (EFO_1001205), Neuromyelitis Optica (EFO_0004256), Anaplastic Large Cell Lymphoma (EFO_0003032), Pulmonary Tuberculosis (EFO_1000049), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Leber Congenital Amaurosis (MONDO_0018998), Autoimmune Disease (EFO_0005140), Urticaria (EFO_0005531), Prostate Carcinoma (EFO_0001663), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Mantle Cell Lymphoma (EFO_1001469), Gangliosidosis (MONDO_0017719), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Hemophilia A (MONDO_0010602), Polymyalgia Rheumatica (EFO_0008518), Dermatomyositis (EFO_0000398), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Anemia, Hemolytic, Autoimmune (EFO_1001264), Duchenne Muscular Dystrophy (MONDO_0010679), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Frontotemporal Dementia (MONDO_0017276), Myeloproliferative Disorder (EFO_0004251), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Non-Small Cell Lung Carcinoma (EFO_0003060), Posterior Uveitis (EFO_1001119), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Langerhans Cell Histiocytosis (EFO_1000318), Primary Myelofibrosis (EFO_0002430), Chorioretinitis (HP_0012424), Pure Red Cell Aplasia (HP_0012410), Oral Lichen Planus (EFO_0008517), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Bell'S Palsy (EFO_0007167), Aids (EFO_0000765), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Hepatitis, Alcoholic (EFO_1001345), Deafness (EFO_0001063), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Psoriatic Arthritis (EFO_0003778), Arthritis (EFO_0005856), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Mycosis Fungoides (EFO_1001051), Tenosynovitis (EFO_1001435), Hypercalcemia (HP_0003072), Exfoliative Dermatitis (EFO_0009456), Microscopic Polyangiitis (EFO_1000784), Central Nervous System Neoplasm (EFO_1000158), Contact Dermatitis (EFO_0005319), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Intermediate Uveitis (EFO_1000986), Pulmonary Sarcoidosis (DOID_13406), Neoplasm Of Mature B-Cells (EFO_0000096), Rhinitis, Allergic, Perennial (EFO_1001417), Respiratory Syncytial Virus Infection (EFO_1001413), Chronic Obstructive Pulmonary Disease (EFO_0000341), Allergic Disease (MONDO_0005271), Erythema Multiforme (EFO_1000694), Chronic Myeloproliferative Disorder (EFO_0002428), Sarcoidosis (MONDO_0019338), Pemphigus (EFO_1000749), Ophthalmic Herpes Zoster (EFO_0007403), Berylliosis (EFO_0007168), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Seborrheic Dermatitis (EFO_1000764), Interstitial Nephritis (MONDO_0001085), Pulmonary Fibrosis (EFO_0009448), Type 2 Diabetes Mellitus (MONDO_0005148), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lymphoproliferative Syndrome (MONDO_0016537), Canavan Disease (MONDO_0010079), Lateral Epicondylitis (EFO_1001896), Esophageal Stricture (HP_0002043), Pneumonia (EFO_0003106), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Hiv-Associated Nephropathy (EFO_0007313), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Ulcerative Colitis (EFO_0000729), B-Cell Neoplasm (MONDO_0004095), Gaucher Disease (MONDO_0018150), Polycythemia Vera (EFO_0002429), Gaucher Disease Type 2 (Orphanet_77260), Prostate Adenocarcinoma (EFO_0000673), Nephrotic Syndrome (EFO_0004255), Hepatitis C Virus Infection (EFO_0003047), Henoch-Schoenlein Purpura (EFO_1000965), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Stiff-Person Syndrome (EFO_0007498), Bullous Pemphigoid (EFO_0007187), Parkinson Disease (MONDO_0005180), Glucose Intolerance (HP_0001952), Acute Graft Vs. Host Disease (EFO_0004599), Polymyositis (EFO_0003063), Membranous Glomerulonephritis (EFO_0004254), Thrombocytopenia (HP_0001873), Synovitis (EFO_0008997), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Meningeal Tuberculosis (EFO_1000039), Subacute Thyroiditis (EFO_1001194), Cardiomyopathy (EFO_0000318), Igg4-Related Disease (MONDO_0017287), Lymphoid Leukemia (EFO_0004289), Cholesterol Embolism (EFO_0005801), Amyotrophic Lateral Sclerosis (MONDO_0004976), Trichinosis (EFO_0007520), Sensorineural Hearing Loss (EFO_1001176), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cystic Fibrosis (MONDO_0009061)", 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5378', 'drugName': 'Meprednisone', 'tradeNames_string': 'Betapar', 'drugSynonyms_string': 'Meprednisone, NSC-527579, SCH 4358, SCH-4358', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1590 | Q17 | What gene does the drug Dipyrone target? | The drug Dipyrone targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dipyrone%" OR LOWER(tradeNames_string) LIKE "%dipyrone%" OR LOWER(drugSynonyms_string) LIKE "%dipyrone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2814', 'drugName': 'Dipyrone', 'tradeNames_string': 'Diprofarn, Novaldin', 'drugSynonyms_string': 'Dipyrone', 'linkedDiseasesDrug_string': 'Sepsis (HP_0100806), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Fever (HP_0001945), Chronic Pain (HP_0012532), Gastroenteritis (EFO_1001463)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4334', 'drugName': 'Dipyrone', 'tradeNames_string': 'Diprofarn, Novaldin', 'drugSynonyms_string': 'Analgin, Dipyrone, Dipyrone anhydrous, Metamizol, Metamizol monohydrate, Metamizole sodium, Metamizole sodium (anhydrous), Metamizole sodium hydrate, Metamizole sodium monohydrate, Metamizolum natricum anhydricum, Methampyrone, NSC-73205, NSC-758445, Noramidopyrine methanesulfonate sodium, Novalgin, Sulpyrine, Sulpyrine hydrate', 'linkedDiseasesDrug_string': 'Sepsis (HP_0100806), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Fever (HP_0001945), Chronic Pain (HP_0012532), Gastroenteritis (EFO_1001463)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1895 | Q17 | What gene does the drug Fosaprepitant Dimeglumine target? | The drug Fosaprepitant Dimeglumine targets the gene TACR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosaprepitant dimeglumine%" OR LOWER(tradeNames_string) LIKE "%fosaprepitant dimeglumine%" OR LOWER(drugSynonyms_string) LIKE "%fosaprepitant dimeglumine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5495', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_string': 'Emend, Fosaprepitant dimeglumine', 'drugSynonyms_string': 'Fosaprepitant (as dimeglumine), Fosaprepitant dimeglumine, Fosaprepitant meglumine, MK-0517', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Sarcoma (EFO_0000691), Post Operative Nausea And Vomiting (EFO_0004888)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.582 | Q17 | What gene does the drug Pf-03715455 target? | The drug Pf-03715455 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAPK14. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-03715455%" OR LOWER(tradeNames_string) LIKE "%pf-03715455%" OR LOWER(drugSynonyms_string) LIKE "%pf-03715455%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5605', 'drugName': 'Pf-03715455', 'tradeNames_string': '', 'drugSynonyms_string': 'PF-03715455, Pf-03715455, Pf-3715455', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK14 (ENSG00000112062)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.314 | Q17 | What gene does the drug Orphenadrine target? | The drug Orphenadrine targets 19 genes: SLC6A2, SCN9A, SCN7A, SCN10A, GRIN3B, SCN4A, SCN8A, GRIN3A, SCN2A, SCN3A, GRIN2B, GRIN2A, SCN5A, GRIN1, SCN1A, SCN11A, HRH1, GRIN2D and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orphenadrine%" OR LOWER(tradeNames_string) LIKE "%orphenadrine%" OR LOWER(drugSynonyms_string) LIKE "%orphenadrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4306', 'drugName': 'Orphenadrine Hydrochloride', 'tradeNames_string': 'Biorphen, Disipal', 'drugSynonyms_string': 'Mephenamin, NSC-82357, Orphenadrine (chloride), Orphenadrine Chloride, Orphenadrine hcl, Orphenadrine hydrochloride', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_6209', 'drugName': 'Orphenadrine Citrate', 'tradeNames_string': 'Norflex, Orphenadrine citrate', 'drugSynonyms_string': 'NSC-757238, Orphenadine citrate, Orphenadrine (citrate), Orphenadrine Citrate, Orphenadrine citrate, Orphenadrine dihydrogen citrate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_6210', 'drugName': 'Orphenadrine Citrate', 'tradeNames_string': 'Norflex, Orphenadrine citrate', 'drugSynonyms_string': 'NSC-757238, Orphenadine citrate, Orphenadrine (citrate), Orphenadrine Citrate, Orphenadrine citrate, Orphenadrine dihydrogen citrate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_6211', 'drugName': 'Orphenadrine Citrate', 'tradeNames_string': 'Norflex, Orphenadrine citrate', 'drugSynonyms_string': 'NSC-757238, Orphenadine citrate, Orphenadrine (citrate), Orphenadrine Citrate, Orphenadrine citrate, Orphenadrine dihydrogen citrate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_4308', 'drugName': 'Orphenadrine Hydrochloride', 'tradeNames_string': 'Biorphen, Disipal', 'drugSynonyms_string': 'Mephenamin, NSC-82357, Orphenadrine (chloride), Orphenadrine Chloride, Orphenadrine hcl, Orphenadrine hydrochloride', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_70', 'drugName': 'Orphenadrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Disipal, Invagesic, Mefenamine, Mialgin, Norflex, Norgesic, Orphenadrin, Orphenadrine, Orphengesic', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Low Back Pain (HP_0003419), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_68', 'drugName': 'Orphenadrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Disipal, Invagesic, Mefenamine, Mialgin, Norflex, Norgesic, Orphenadrin, Orphenadrine, Orphengesic', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Low Back Pain (HP_0003419), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_67', 'drugName': 'Orphenadrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Disipal, Invagesic, Mefenamine, Mialgin, Norflex, Norgesic, Orphenadrin, Orphenadrine, Orphengesic', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Low Back Pain (HP_0003419), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_6212', 'drugName': 'Orphenadrine Citrate', 'tradeNames_string': 'Norflex, Orphenadrine citrate', 'drugSynonyms_string': 'NSC-757238, Orphenadine citrate, Orphenadrine (citrate), Orphenadrine Citrate, Orphenadrine citrate, Orphenadrine dihydrogen citrate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_4307', 'drugName': 'Orphenadrine Hydrochloride', 'tradeNames_string': 'Biorphen, Disipal', 'drugSynonyms_string': 'Mephenamin, NSC-82357, Orphenadrine (chloride), Orphenadrine Chloride, Orphenadrine hcl, Orphenadrine hydrochloride', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_4305', 'drugName': 'Orphenadrine Hydrochloride', 'tradeNames_string': 'Biorphen, Disipal', 'drugSynonyms_string': 'Mephenamin, NSC-82357, Orphenadrine (chloride), Orphenadrine Chloride, Orphenadrine hcl, Orphenadrine hydrochloride', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_69', 'drugName': 'Orphenadrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Disipal, Invagesic, Mefenamine, Mialgin, Norflex, Norgesic, Orphenadrin, Orphenadrine, Orphengesic', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Low Back Pain (HP_0003419), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 19}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1962 | Q17 | What gene does the drug Icotinib target? | The drug Icotinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%icotinib%" OR LOWER(tradeNames_string) LIKE "%icotinib%" OR LOWER(drugSynonyms_string) LIKE "%icotinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5477', 'drugName': 'Icotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'BPI-2009H, Bpi-2009, Icotinib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Psoriasis (EFO_0000676), Lung Adenocarcinoma (EFO_0000571), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Squamous Cell Lung Carcinoma (EFO_0000708), Bronchial Neoplasm (EFO_1000849), Carcinoma (EFO_0000313), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_477', 'drugName': 'Edicotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Edicotinib, JNJ-40346527, Jnj-40346527', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Prostate Adenocarcinoma (EFO_0000673), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF1R (ENSG00000182578)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.387 | Q17 | What gene does the drug Pirenzepine target? | The drug Pirenzepine targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pirenzepine%" OR LOWER(tradeNames_string) LIKE "%pirenzepine%" OR LOWER(drugSynonyms_string) LIKE "%pirenzepine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5044', 'drugName': 'Pirenzepine', 'tradeNames_string': 'Gastri p, Gastrozepin', 'drugSynonyms_string': 'ACI-91, Pirenzepine', 'linkedDiseasesDrug_string': 'Peptic Ulcer (HP_0004398), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.541 | Q17 | What gene does the drug Procaine Hydrochloride target? | The drug Procaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%procaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%procaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%procaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2951', 'drugName': 'Procaine Hydrochloride', 'tradeNames_string': 'Novocain, Pasconeural n, Procaine hydrochloride', 'drugSynonyms_string': 'Anestil, Enpro, Jenacaine, Medaject, NSC-757280, Naucaine, Neocaine, Omnicain, Planocaine, Procaine hcl, Procaine hydrochloride, Procaini hydrochloridum, Rocain, SP-01A, SP01A, Sp01a, Syntocain', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2193', 'drugName': 'Chloroprocaine Hydrochloride', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugSynonyms_string': 'Chloroprocaine HCl, Chloroprocaine hcl, Chloroprocaine hydrochloride, Chlorprocaine chloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2819', 'drugName': 'Benoxinate Hydrochloride', 'tradeNames_string': 'Benoxinate hydrochloride', 'drugSynonyms_string': 'Benoxinate hcl, Benoxinate hydrochloride, NSC-759847, Oxibuprocaine chloride, Oxybuprocaine hcl, Oxybuprocaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.431 | Q17 | What gene does the drug Remifentanil Hydrochloride target? | The drug Remifentanil Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remifentanil hydrochloride%" OR LOWER(tradeNames_string) LIKE "%remifentanil hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%remifentanil hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_577', 'drugName': 'Remifentanil Hydrochloride', 'tradeNames_string': 'Ultiva', 'drugSynonyms_string': 'GI 87084B, GI-87084B, Remifentanil hcl, Remifentanil hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.657 | Q17 | What gene does the drug Anileridine Phosphate target? | The drug Anileridine Phosphate targets 2 genes: OPRK1 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anileridine phosphate%" OR LOWER(tradeNames_string) LIKE "%anileridine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%anileridine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4938', 'drugName': 'Anileridine Phosphate', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Anileridine phosphate, Leritine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4939', 'drugName': 'Anileridine Phosphate', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Anileridine phosphate, Leritine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1642 | Q17 | What gene does the drug Decamethonium Bromide target? | The drug Decamethonium Bromide targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%decamethonium bromide%" OR LOWER(tradeNames_string) LIKE "%decamethonium bromide%" OR LOWER(drugSynonyms_string) LIKE "%decamethonium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5170', 'drugName': 'Decamethonium Bromide', 'tradeNames_string': 'Syncurine', 'drugSynonyms_string': 'Decamethonium Bromide, Decamethonium bromide, Decamethonium diiodide, Decamethonium iodide, NSC-23004', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1318 | Q17 | What gene does the drug Amoxapine target? | The drug Amoxapine targets 7 genes: SLC6A2, DRD4, DRD1, SLC6A4, DRD2, DRD5 and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amoxapine%" OR LOWER(tradeNames_string) LIKE "%amoxapine%" OR LOWER(drugSynonyms_string) LIKE "%amoxapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2376', 'drugName': 'Amoxapine', 'tradeNames_string': 'Amoxapine, Asendin, Asendis, Defanyl', 'drugSynonyms_string': 'Amoxapine, CL 67,772, CL 67772, CL-67,772, CL-67772, NSC-759559', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_2377', 'drugName': 'Amoxapine', 'tradeNames_string': 'Amoxapine, Asendin, Asendis, Defanyl', 'drugSynonyms_string': 'Amoxapine, CL 67,772, CL 67772, CL-67,772, CL-67772, NSC-759559', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_2378', 'drugName': 'Amoxapine', 'tradeNames_string': 'Amoxapine, Asendin, Asendis, Defanyl', 'drugSynonyms_string': 'Amoxapine, CL 67,772, CL 67772, CL-67,772, CL-67772, NSC-759559', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1358 | Q17 | What gene does the drug Nomifensine Maleate target? | The drug Nomifensine Maleate targets 3 genes: SLC6A4, SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nomifensine maleate%" OR LOWER(tradeNames_string) LIKE "%nomifensine maleate%" OR LOWER(drugSynonyms_string) LIKE "%nomifensine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2665', 'drugName': 'Nomifensine Maleate', 'tradeNames_string': 'Merital', 'drugSynonyms_string': 'HOE 984, HOE-984, Hostalival, NSC-289114, Nomifensine hydrogen maleate, Nomifensine maleate, Psicronizer', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.414 | Q17 | What gene does the drug Ubrogepant target? | The drug Ubrogepant targets the gene CALCRL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ubrogepant%" OR LOWER(tradeNames_string) LIKE "%ubrogepant%" OR LOWER(drugSynonyms_string) LIKE "%ubrogepant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_528', 'drugName': 'Ubrogepant', 'tradeNames_string': 'Ubrelvy', 'drugSynonyms_string': 'MK-1602, Ubrogepant, Ubrogepant anhydrous', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1615 | Q17 | What gene does the drug Diphemanil Methylsulfate target? | The drug Diphemanil Methylsulfate targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diphemanil methylsulfate%" OR LOWER(tradeNames_string) LIKE "%diphemanil methylsulfate%" OR LOWER(drugSynonyms_string) LIKE "%diphemanil methylsulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1327', 'drugName': 'Diphemanil Methylsulfate', 'tradeNames_string': 'Prantal', 'drugSynonyms_string': 'Diphemanil methylsulfate, Diphemanil methylsulphate, Diphemanil metilsulfate, NSC-41725', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1328', 'drugName': 'Diphemanil Methylsulfate', 'tradeNames_string': 'Prantal', 'drugSynonyms_string': 'Diphemanil methylsulfate, Diphemanil methylsulphate, Diphemanil metilsulfate, NSC-41725', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.687 | Q17 | What gene does the drug Bi-671800 target? | The drug Bi-671800 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PTGDR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bi-671800%" OR LOWER(tradeNames_string) LIKE "%bi-671800%" OR LOWER(drugSynonyms_string) LIKE "%bi-671800%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5746', 'drugName': 'Bi-671800', 'tradeNames_string': '', 'drugSynonyms_string': 'Actimis, BI 671800, BI671800, Bi 671800, Bi-671800', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.621 | Q17 | What gene does the drug Begacestat target? | The drug Begacestat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: APH1A, APH1B, PSEN1, PSENEN, NCSTN and PSEN2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%begacestat%" OR LOWER(tradeNames_string) LIKE "%begacestat%" OR LOWER(drugSynonyms_string) LIKE "%begacestat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6270', 'drugName': 'Begacestat', 'tradeNames_string': '', 'drugSynonyms_string': 'Begacestat, GSI-953', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'APH1A (ENSG00000117362), PSENEN (ENSG00000205155), APH1B (ENSG00000138613), PSEN1 (ENSG00000080815), NCSTN (ENSG00000162736), PSEN2 (ENSG00000143801)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.923 | Q17 | What gene does the drug Vedolizumab target? | The drug Vedolizumab targets 2 genes: ITGB7 and ITGA4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vedolizumab%" OR LOWER(tradeNames_string) LIKE "%vedolizumab%" OR LOWER(drugSynonyms_string) LIKE "%vedolizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5088', 'drugName': 'Vedolizumab', 'tradeNames_string': 'Entyvio', 'drugSynonyms_string': 'LDP-02, LDP02, MLN-0002, MLN-02, MLN0002, MLN02, Vedolizumab', 'linkedDiseasesDrug_string': "Hiv Infection (EFO_0000764), Infection (EFO_0000544), Crohn'S Disease (EFO_0000384), Ulcerative Colitis (EFO_0000729), Melanoma (EFO_0000756), Hiv-1 Infection (EFO_0000180), Colitis (EFO_0003872), Type 1 Diabetes Mellitus (MONDO_0005147), Celiac Disease (EFO_0001060), Immune System Disease (EFO_0000540), Inflammatory Bowel Disease (EFO_0003767)", 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1199 | Q17 | What gene does the drug Tesamorelin target? | The drug Tesamorelin targets the gene GHRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tesamorelin%" OR LOWER(tradeNames_string) LIKE "%tesamorelin%" OR LOWER(drugSynonyms_string) LIKE "%tesamorelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2825', 'drugName': 'Tesamorelin', 'tradeNames_string': '', 'drugSynonyms_string': 'TH-9507, TH9507, Tesamorelin', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Chronic Obstructive Pulmonary Disease (EFO_0000341), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHRHR (ENSG00000106128)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4100', 'drugName': 'Tesamorelin Acetate', 'tradeNames_string': 'Egrifta', 'drugSynonyms_string': 'TH9507, Tesamorelin acetate', 'linkedDiseasesDrug_string': 'Hiv-Associated Lipodystrophy Syndrome (EFO_1001348)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHRHR (ENSG00000106128)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.839 | Q17 | What gene does the drug Sitagliptin target? | The drug Sitagliptin targets the gene DPP4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sitagliptin%" OR LOWER(tradeNames_string) LIKE "%sitagliptin%" OR LOWER(drugSynonyms_string) LIKE "%sitagliptin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugSynonyms_string': 'Glactiv, MK-0431, MK0431, ONO-5435, Sitagliptin monophosphate, Sitagliptin monophosphate anhydrous, Sitagliptin monophosphate monohydrate, Sitagliptin phosphate, Sitagliptin phosphate anhydrous, Sitagliptin phosphate hydrate, Sitagliptin phosphate monohydrate', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3574', 'drugName': 'Sitagliptin', 'tradeNames_string': 'Januvia', 'drugSynonyms_string': 'LEZ-763, LEZ763, MK-0431, Sitagliptin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Psoriasis (EFO_0000676), Hyperlipidemia (MONDO_0021187), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Acute Myocardial Infarction (EFO_0008583), Diabetic Foot (EFO_1001459), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Glucose Intolerance (HP_0001952), Acute Graft Vs. Host Disease (EFO_0004599), Renal Insufficiency (HP_0000083), Abnormal Glucose Tolerance (EFO_0002546), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Hiv-1 Infection (EFO_0000180), Chronic Kidney Disease (EFO_0003884), Prediabetes Syndrome (EFO_1001121), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1771 | Q17 | What gene does the drug Ribociclib target? | The drug Ribociclib targets 2 genes: CDK4 and CDK6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ribociclib%" OR LOWER(tradeNames_string) LIKE "%ribociclib%" OR LOWER(drugSynonyms_string) LIKE "%ribociclib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3488', 'drugName': 'Ribociclib', 'tradeNames_string': '', 'drugSynonyms_string': 'LEE-011, LEE-011A, LEE011, LEE011A, Lee-011, NVP-LEE011, Ribociclib', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Teratoma (MONDO_0002601), Neuroblastoma (EFO_0000621), Peritoneal Neoplasm (EFO_1001100), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Uterine Neoplasm (EFO_0003859), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Dedifferentiated Liposarcoma (EFO_0003085), Pulmonary Neuroendocrine Tumor (EFO_0005220), Neuroendocrine Neoplasm (EFO_1001901), Soft Tissue Sarcoma (EFO_1001968), Carcinoma (EFO_0000313), Thymus Neoplasm (EFO_0002626), Fallopian Tube Cancer (MONDO_0002158), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Neoplasm (EFO_0000616), Malignant Rhabdoid Tumour (EFO_0005701), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3487', 'drugName': 'Ribociclib', 'tradeNames_string': '', 'drugSynonyms_string': 'LEE-011, LEE-011A, LEE011, LEE011A, Lee-011, NVP-LEE011, Ribociclib', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Teratoma (MONDO_0002601), Neuroblastoma (EFO_0000621), Peritoneal Neoplasm (EFO_1001100), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Anaplastic Astrocytoma (EFO_0002499), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Uterine Neoplasm (EFO_0003859), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Dedifferentiated Liposarcoma (EFO_0003085), Pulmonary Neuroendocrine Tumor (EFO_0005220), Neuroendocrine Neoplasm (EFO_1001901), Soft Tissue Sarcoma (EFO_1001968), Carcinoma (EFO_0000313), Thymus Neoplasm (EFO_0002626), Fallopian Tube Cancer (MONDO_0002158), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Neoplasm (EFO_0000616), Malignant Rhabdoid Tumour (EFO_0005701), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2093', 'drugName': 'Ribociclib Succinate', 'tradeNames_string': 'Kisqali', 'drugSynonyms_string': 'Birociclib, LEE-011-BBA, LEE011-BBA, Ribociclib succinate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2092', 'drugName': 'Ribociclib Succinate', 'tradeNames_string': 'Kisqali', 'drugSynonyms_string': 'Birociclib, LEE-011-BBA, LEE011-BBA, Ribociclib succinate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.953 | Q17 | What gene does the drug Interferon Alfa-N3 target? | The drug Interferon Alfa-N3 targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon alfa-n3%" OR LOWER(tradeNames_string) LIKE "%interferon alfa-n3%" OR LOWER(drugSynonyms_string) LIKE "%interferon alfa-n3%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_404', 'drugName': 'Interferon Alfa-N3', 'tradeNames_string': 'Alferon ldo, Alferon n gel, Alferon n injection', 'drugSynonyms_string': '.alpha.-interferons, Alferon, Alferon n, Interferon alfa-n3, Interferon alpha-n3, Leukocyte interferon', 'linkedDiseasesDrug_string': 'Severe Acute Respiratory Syndrome (EFO_0000694), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.185 | Q17 | What gene does the drug Argipressin Tannate target? | The drug Argipressin Tannate targets 3 genes: AVPR2, AVPR1A and AVPR1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%argipressin tannate%" OR LOWER(tradeNames_string) LIKE "%argipressin tannate%" OR LOWER(drugSynonyms_string) LIKE "%argipressin tannate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5273', 'drugName': 'Argipressin Tannate', 'tradeNames_string': 'Pitressin tannate (synthetic)', 'drugSynonyms_string': 'Argipressin, Argipressin tannate, CI-107', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1072 | Q17 | What gene does the drug Butamben Picrate target? | The drug Butamben Picrate targets 2 genes: TRPV4 and TRPA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%butamben picrate%" OR LOWER(tradeNames_string) LIKE "%butamben picrate%" OR LOWER(drugSynonyms_string) LIKE "%butamben picrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_268', 'drugName': 'Butamben Picrate', 'tradeNames_string': '', 'drugSynonyms_string': 'ABBOTT-34842, Butamben picrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPV4 (ENSG00000111199), TRPA1 (ENSG00000104321)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_269', 'drugName': 'Butamben Picrate', 'tradeNames_string': '', 'drugSynonyms_string': 'ABBOTT-34842, Butamben picrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPV4 (ENSG00000111199), TRPA1 (ENSG00000104321)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.711 | Q17 | What gene does the drug Chloroprocaine target? | The drug Chloroprocaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chloroprocaine%" OR LOWER(tradeNames_string) LIKE "%chloroprocaine%" OR LOWER(drugSynonyms_string) LIKE "%chloroprocaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1606', 'drugName': 'Chloroprocaine', 'tradeNames_string': '', 'drugSynonyms_string': '2-chloroprocaine, Chloroprocaine', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Pregnancy (EFO_0002950), Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2193', 'drugName': 'Chloroprocaine Hydrochloride', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugSynonyms_string': 'Chloroprocaine HCl, Chloroprocaine hcl, Chloroprocaine hydrochloride, Chlorprocaine chloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.173 | Q17 | What gene does the drug 9-Aminocamptothecin target? | The drug 9-Aminocamptothecin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%9-aminocamptothecin%" OR LOWER(tradeNames_string) LIKE "%9-aminocamptothecin%" OR LOWER(drugSynonyms_string) LIKE "%9-aminocamptothecin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_121', 'drugName': '9-Aminocamptothecin', 'tradeNames_string': '', 'drugSynonyms_string': '9-amino-20(s)-camptothecin, 9-aminocamptothecin, Aminocamptothecin, NSC-603071', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Lung Cancer (MONDO_0008903), Kidney Cancer (MONDO_0002367), Lymphoma (EFO_0000574), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Ovarian Neoplasm (EFO_0003893), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.296 | Q17 | What gene does the drug Benoxinate target? | The drug Benoxinate targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benoxinate%" OR LOWER(tradeNames_string) LIKE "%benoxinate%" OR LOWER(drugSynonyms_string) LIKE "%benoxinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1754', 'drugName': 'Benoxinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Benoxinate, Conjucain, Dorsacain, Monofree oxybuprocaine, Oxybucaine, Oxybuprocaine', 'linkedDiseasesDrug_string': 'Pruritus (HP_0000989)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2819', 'drugName': 'Benoxinate Hydrochloride', 'tradeNames_string': 'Benoxinate hydrochloride', 'drugSynonyms_string': 'Benoxinate hcl, Benoxinate hydrochloride, NSC-759847, Oxibuprocaine chloride, Oxybuprocaine hcl, Oxybuprocaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.554 | Q17 | What gene does the drug Carteolol Hydrochloride target? | The drug Carteolol Hydrochloride targets 3 genes: ADRB3, ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carteolol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%carteolol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%carteolol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1755', 'drugName': 'Carteolol Hydrochloride', 'tradeNames_string': 'Carteolol hydrochloride, Cartrol, Ocupress, Teoptic', 'drugSynonyms_string': 'ABBOTT-43326, Carteolol hcl, Carteolol hydrochloride, NSC-300906, OPC-1085', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.763 | Q17 | What gene does the drug Denosumab target? | The drug Denosumab targets the gene TNFSF11. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%denosumab%" OR LOWER(tradeNames_string) LIKE "%denosumab%" OR LOWER(drugSynonyms_string) LIKE "%denosumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1723', 'drugName': 'Denosumab', 'tradeNames_string': 'Prolia, Prolia, Ranmark Xgeva, Prolia, xgeva, Xgeva', 'drugSynonyms_string': 'AMG 162, AMG-162, Denosumab, Denosumab biosimilar (ql-1206), Denosumab biosimilar tk-006, QL-1206, QL1206, Ql1206, TK-006, TK006', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Langerhans Cell Histiocytosis (EFO_1000318), Postmenopausal Osteoporosis (EFO_0003854), Male Infertility (EFO_0004248), Fibrous Dysplasia (MONDO_0000845), Bone Giant Cell Tumor (EFO_0007176), Anorexia Nervosa (MONDO_0005351), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma (EFO_0000305), Osteoporosis (EFO_0003882), Bone Disease (EFO_0004260), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Crohn'S Disease (EFO_0000384), Hypercalcemia (HP_0003072), Bone Fracture (EFO_0003931), Metastasis (EFO_0009708), Bone Metastasis (EFO_0009870), Inflammatory Breast Carcinoma (EFO_1000984), Aortic Stenosis (EFO_0000266), Osteoarthritis, Hip (EFO_1000786), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Allergic Disease (MONDO_0005271), Cutaneous Melanoma (EFO_0000389), Osteogenesis Imperfecta (MONDO_0019019), Gout (EFO_0004274), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Giant Cell Tumor (MONDO_0002171), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086)", 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFSF11 (ENSG00000120659)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.304 | Q17 | What gene does the drug Daunorubicin Hydrochloride target? | The drug Daunorubicin Hydrochloride targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daunorubicin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%daunorubicin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%daunorubicin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1919', 'drugName': 'Daunorubicin Hydrochloride', 'tradeNames_string': 'Cerubidine, Daunorubicin hydrochloride, Daunoxome', 'drugSynonyms_string': 'Daunorubicin (as hydrochloride), Daunorubicin hcl, Daunorubicin hydrochloride, FI 6339 HYDROCHLORIDE, FI 6339 [AS THE BASE], FI-6339, FI-6339 HYDROCHLORIDE, NDC 0082-4155, NDC-0082-4155, NSC-82151, RP 13057 HYDROCHLORIDE, RP 13057 [AS THE BASE), RP-13057, RP-13057 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Refractory Anemia (EFO_0003802), Myelodysplastic Syndrome (EFO_0000198), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Acute Myelomonocytic Leukemia (EFO_0000223), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Basophilic Leukemia (EFO_0003029), Acute Megakaryoblastic Leukaemia (EFO_0003025), Refractory Anemia With Excess Blasts (EFO_0003811), Acute Erythroleukemia (EFO_0000218), T-Lymphoblastic Lymphoma (MONDO_0044917), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Sarcoma (EFO_0000691), Acute Myeloblastic Leukemia With Maturation (EFO_0003028), Acute Monocytic Leukemia (EFO_0000221)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1878 | Q17 | What gene does the drug Desvenlafaxine Succinate target? | The drug Desvenlafaxine Succinate targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desvenlafaxine succinate%" OR LOWER(tradeNames_string) LIKE "%desvenlafaxine succinate%" OR LOWER(drugSynonyms_string) LIKE "%desvenlafaxine succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_735', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugSynonyms_string': 'DVS-233, Desvenlafaxine succinate, Desvenlafaxine succinate anhydrous, Desvenlafaxine succinate hydrate, Desvenlafaxine succinate monohydrate, Dvs anhydrous, O-desmethyl venlafaxine succinate, O-desmethylvenlafaxine succinate, WY-45233, WY45233', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_736', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugSynonyms_string': 'DVS-233, Desvenlafaxine succinate, Desvenlafaxine succinate anhydrous, Desvenlafaxine succinate hydrate, Desvenlafaxine succinate monohydrate, Dvs anhydrous, O-desmethyl venlafaxine succinate, O-desmethylvenlafaxine succinate, WY-45233, WY45233', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1093 | Q17 | What gene does the drug Pseudoephedrine Hydrochloride target? | The drug Pseudoephedrine Hydrochloride targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pseudoephedrine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%pseudoephedrine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pseudoephedrine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_151', 'drugName': 'Pseudoephedrine Hydrochloride', 'tradeNames_string': 'Actifed, Contac, Dimotane plus, Dimotane plus l.a., Galpseud, Galpseud plus, Novafed, Otrivine mu-cron, Pseudoephedrine hydrochloride, Pseudophed, Sinutab, Sudafed, Sudafed 12 hour, Sudafed 12 hr decongest, Sudafed 24 hour, Sudafed plus, Sudafed-sa', 'drugSynonyms_string': 'Efidac 24, Galsud, NSC-106567, NSC-33634, Otrinol, Pseudoephedrine hcl, Pseudoephedrine hydrochloride, Rhinalair', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Enuresis (MONDO_0024290), Seasonal Allergic Rhinitis (EFO_0003956), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1747 | Q17 | What gene does the drug Brompheniramine Maleate target? | The drug Brompheniramine Maleate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brompheniramine maleate%" OR LOWER(tradeNames_string) LIKE "%brompheniramine maleate%" OR LOWER(drugSynonyms_string) LIKE "%brompheniramine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1014', 'drugName': 'Brompheniramine Maleate', 'tradeNames_string': 'Brompheniramine maleate, Dimegan, Dimetane, Dimetane-ten, Dimotane, Dimotane l.a.', 'drugSynonyms_string': '(+)-Brompheniramine Maleate, Brompheniramine fumarate, Brompheniramine maleate, NSC-758652, Parabromdylamine maleate', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_431', 'drugName': 'Dexbrompheniramine Maleate', 'tradeNames_string': 'Disomer', 'drugSynonyms_string': 'Brompheniramine d-form maleate, Dexbrompheniramine fumarate, Dexbrompheniramine maleate', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1652 | Q17 | What gene does the drug Bitolterol Mesylate target? | The drug Bitolterol Mesylate targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bitolterol mesylate%" OR LOWER(tradeNames_string) LIKE "%bitolterol mesylate%" OR LOWER(drugSynonyms_string) LIKE "%bitolterol mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3535', 'drugName': 'Bitolterol Mesylate', 'tradeNames_string': 'Tomalate, Tornalate', 'drugSynonyms_string': 'Bitolterol mesilate, Bitolterol mesylate, Bitolterol methanesulfonate, WIN 32,784, WIN-32784', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.914 | Q17 | What gene does the drug Phensuximide target? | The drug Phensuximide targets 3 genes: CACNA1G, CACNA1I and CACNA1H. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phensuximide%" OR LOWER(tradeNames_string) LIKE "%phensuximide%" OR LOWER(drugSynonyms_string) LIKE "%phensuximide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1498', 'drugName': 'Phensuximide', 'tradeNames_string': 'Milontin', 'drugSynonyms_string': '1-methyl-3-phenylsuccinimide, Epimid, Lifene, Milonton, Mirontin, N-methyl-3-phenylpyrrolidinedione, NSC-760079, PM-334, Phensuximid, Phensuximide, Racemic phensuximide, Succitimal', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1932 | Q17 | What gene does the drug Histamine target? | The drug Histamine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%histamine%" OR LOWER(tradeNames_string) LIKE "%histamine%" OR LOWER(drugSynonyms_string) LIKE "%histamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2616', 'drugName': 'Histamine', 'tradeNames_string': '', 'drugSynonyms_string': '.beta.-aminoethylglyoxaline, Ergamine, Ergotidine, Histamine, NSC-33792', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Non-Hodgkins Lymphoma (EFO_0005952), Pterygium (EFO_0000678), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Multiple Sclerosis (MONDO_0005301), Seasonal Allergic Rhinitis (EFO_0003956), Cutaneous Melanoma (EFO_0000389), Osteoarthritis, Knee (EFO_0004616), Kidney Cancer (MONDO_0002367), Inflammation (MP_0001845), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2637', 'drugName': 'Terfenadine', 'tradeNames_string': 'Antihistamine, Histafen, Histafen 120, Seldane, Terfenor, Terfenor fte, Terfex, Terfinax 120, Terfinax 60, Triludan, Triludan fte', 'drugSynonyms_string': 'NSC-665802, NSC-758627, RMI 9918, RMI-9918, Terfenadine', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Asthma (MONDO_0004979), Hepatitis B Virus Infection (EFO_0004197), Multiple Sclerosis (MONDO_0005301), Hepatitis D Virus Infection (EFO_0007304), Chronic Progressive Multiple Sclerosis (EFO_0003840), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Disease (MONDO_0005271), Peanut Allergic Reaction (EFO_0007425)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2178', 'drugName': 'Histamine Phosphate', 'tradeNames_string': 'Histamine phosphate', 'drugSynonyms_string': 'Histamine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.275 | Q17 | What gene does the drug Dalcetrapib target? | The drug Dalcetrapib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CETP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dalcetrapib%" OR LOWER(tradeNames_string) LIKE "%dalcetrapib%" OR LOWER(drugSynonyms_string) LIKE "%dalcetrapib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4061', 'drugName': 'Dalcetrapib', 'tradeNames_string': '', 'drugSynonyms_string': 'Dalcetrapib, JTT-705, RO-4607381, RO4607381', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentration (HP_0003119), Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Peripheral Arterial Disease (EFO_0004265), Covid-19 (MONDO_0100096), Cardiovascular Disease (EFO_0000319), Acute Coronary Syndrome (EFO_0005672), Disorder Of Lipid Metabolism (Orphanet_309005)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CETP (ENSG00000087237)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1147 | Q17 | What gene does the drug Codeine Phosphate target? | The drug Codeine Phosphate targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%codeine phosphate%" OR LOWER(tradeNames_string) LIKE "%codeine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%codeine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4198', 'drugName': 'Dihydrocodeine Bitartrate', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine, dihydro-, tartrate (1:1), DF 118, DF-118, Dihydrocodeine bitartrate, Dihydrocodeine bitartrate cii, Dihydrocodeine hydrogen tartrate, Dihydrocodeine phosphate, Dihydrocodeine tartrate, Dihydroneopine, Drocode, NSC-117857', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1990', 'drugName': 'Codeine Phosphate', 'tradeNames_string': 'Ambenyl cough syrup, Bepro, Colrex compound, Evacode, Galcodine', 'drugSynonyms_string': 'Codeine phosphate, Codeine phosphate anhydrous, Codeine phosphate bp, Codeine phosphate cii, Codeine phosphate hemihydrate, Codeine phosphate hydrate, Codeini phosphas, Methylmorphine', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Hiv Infection (EFO_0000764), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pain (EFO_0003843), Muscle Spasm (HP_0003394)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1589 | Q17 | What gene does the drug Basimglurant target? | The drug Basimglurant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GRM5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%basimglurant%" OR LOWER(tradeNames_string) LIKE "%basimglurant%" OR LOWER(drugSynonyms_string) LIKE "%basimglurant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_784', 'drugName': 'Basimglurant', 'tradeNames_string': '', 'drugSynonyms_string': 'Basimglurant, NOE-101, RG-7090, RO-4917523, RO4917523, Rg7090', 'linkedDiseasesDrug_string': 'Fragile X Syndrome (MONDO_0010383), Major Depressive Disorder (MONDO_0002009), Tuberous Sclerosis (MONDO_0001734), Depressive Disorder (MONDO_0002050), Trigeminal Neuralgia (EFO_1001219)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM5 (ENSG00000168959)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.700 | Q17 | What gene does the drug Aprepitant target? | The drug Aprepitant targets the gene TACR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aprepitant%" OR LOWER(tradeNames_string) LIKE "%aprepitant%" OR LOWER(drugSynonyms_string) LIKE "%aprepitant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1299', 'drugName': 'Aprepitant', 'tradeNames_string': 'Aprepitant, Cinvanti, Emend', 'drugSynonyms_string': 'Aprepitant, L-754,030, MK-0869, MK-869, NSC-748825', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Gastroparesis (EFO_1000948), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Nausea And Vomiting (HP_0002017), Non-Small Cell Lung Carcinoma (EFO_0003060), Major Depressive Disorder (MONDO_0002009), Vomiting (HP_0002013), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5495', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_string': 'Emend, Fosaprepitant dimeglumine', 'drugSynonyms_string': 'Fosaprepitant (as dimeglumine), Fosaprepitant dimeglumine, Fosaprepitant meglumine, MK-0517', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Sarcoma (EFO_0000691), Post Operative Nausea And Vomiting (EFO_0004888)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_542', 'drugName': 'Fosaprepitant', 'tradeNames_string': 'Ivemend', 'drugSynonyms_string': 'Fosaprepitant, L-758298', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Nasopharyngeal Neoplasm (EFO_0004252), Sarcoma (EFO_0000691), Female Reproductive System Neoplasm (MONDO_0021148), Post Operative Nausea And Vomiting (EFO_0004888), Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1765 | Q17 | What gene does the drug Tiotropium Bromide target? | The drug Tiotropium Bromide targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tiotropium bromide%" OR LOWER(tradeNames_string) LIKE "%tiotropium bromide%" OR LOWER(drugSynonyms_string) LIKE "%tiotropium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4878', 'drugName': 'Tiotropium Bromide', 'tradeNames_string': 'Spiriva, Spiriva respimat', 'drugSynonyms_string': 'BA 679 BR, BA-679 BR, BA-679-BR, BA-679BR, Tiotropium bromide, Tiotropium bromide anhydrous, Tiotropium bromide hydrate, Tiotropium bromide monohydrate', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Neoplasm (EFO_0000616), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Cystic Fibrosis (MONDO_0009061), Renal Insufficiency (HP_0000083), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.488 | Q17 | What gene does the drug Diphenylpyraline target? | The drug Diphenylpyraline targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diphenylpyraline%" OR LOWER(tradeNames_string) LIKE "%diphenylpyraline%" OR LOWER(drugSynonyms_string) LIKE "%diphenylpyraline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6116', 'drugName': 'Diphenylpyraline', 'tradeNames_string': '', 'drugSynonyms_string': 'Diphenylpyraline', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4165', 'drugName': 'Diphenylpyraline Hydrochloride', 'tradeNames_string': 'Hispril, Histryl, Histryl paed, Lergoban', 'drugSynonyms_string': 'Diphenylpyraline HCl, Diphenylpyraline hcl, Diphenylpyraline hydrochloride, Diphenylpyraline teoclate, NSC-61825', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.428 | Q17 | What gene does the drug Siponimod Fumarate target? | The drug Siponimod Fumarate targets the gene S1PR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%siponimod fumarate%" OR LOWER(tradeNames_string) LIKE "%siponimod fumarate%" OR LOWER(drugSynonyms_string) LIKE "%siponimod fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4451', 'drugName': 'Siponimod Fumarate', 'tradeNames_string': 'Mayzent', 'drugSynonyms_string': 'NVP-BAF312-AEA, Siponimod fumarate, Siponimod fumaric acid, Siponimod hemifumarate, Siponimod hemifumaric acid', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Chronic Progressive Multiple Sclerosis (EFO_0003840)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.377 | Q17 | What gene does the drug Exemestane target? | The drug Exemestane targets the gene CYP19A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%exemestane%" OR LOWER(tradeNames_string) LIKE "%exemestane%" OR LOWER(drugSynonyms_string) LIKE "%exemestane%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_923', 'drugName': 'Exemestane', 'tradeNames_string': 'Aromasin, Exemestane', 'drugSynonyms_string': 'Exemestane, FCE-24304, FCE24304, NSC-758907, PNU-155971', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Endometrial Cancer (MONDO_0011962), Non-Small Cell Lung Carcinoma (EFO_0003060), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Atypical Endometrial Hyperplasia (EFO_1000098), Breast Ductal Carcinoma In Situ (EFO_0000432), Breast Carcinoma In Situ (MONDO_0004658), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1008 | Q17 | What gene does the drug Panobinostat Lactate target? | The drug Panobinostat Lactate targets 11 genes: HDAC4, HDAC3, HDAC2, HDAC1, HDAC5, HDAC7, HDAC8, HDAC9, HDAC11, HDAC6 and HDAC10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%panobinostat lactate%" OR LOWER(tradeNames_string) LIKE "%panobinostat lactate%" OR LOWER(drugSynonyms_string) LIKE "%panobinostat lactate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5237', 'drugName': 'Panobinostat Lactate', 'tradeNames_string': 'Farydak', 'drugSynonyms_string': 'Panobinostat lactate, Panobinostat lactate anhydrous', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'numberLinkedTargets': 11}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1003 | Q17 | What gene does the drug Flavoxate target? | The drug Flavoxate targets 8 genes: PDE7B, PDE7A, PDE8A, PDE4D, PDE4B, PDE4A, PDE4C and PDE8B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flavoxate%" OR LOWER(tradeNames_string) LIKE "%flavoxate%" OR LOWER(drugSynonyms_string) LIKE "%flavoxate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_766', 'drugName': 'Flavoxate', 'tradeNames_string': '', 'drugSynonyms_string': 'Bladuril, Flavoxate', 'linkedDiseasesDrug_string': 'Polyuria (HP_0000103), Prostatitis (EFO_0003830), Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Urinary Incontinence (HP_0000020), Dysuria (EFO_0003901)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1988', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1987', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_764', 'drugName': 'Flavoxate', 'tradeNames_string': '', 'drugSynonyms_string': 'Bladuril, Flavoxate', 'linkedDiseasesDrug_string': 'Polyuria (HP_0000103), Prostatitis (EFO_0003830), Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Urinary Incontinence (HP_0000020), Dysuria (EFO_0003901)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_765', 'drugName': 'Flavoxate', 'tradeNames_string': '', 'drugSynonyms_string': 'Bladuril, Flavoxate', 'linkedDiseasesDrug_string': 'Polyuria (HP_0000103), Prostatitis (EFO_0003830), Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Urinary Incontinence (HP_0000020), Dysuria (EFO_0003901)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1989', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1940 | Q17 | What gene does the drug Vernakalant target? | The drug Vernakalant targets 6 genes: KCND3, KCNJ3, KCNJ5, SCN5A, KCNA5 and KCNH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vernakalant%" OR LOWER(tradeNames_string) LIKE "%vernakalant%" OR LOWER(drugSynonyms_string) LIKE "%vernakalant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_716', 'drugName': 'Vernakalant', 'tradeNames_string': '', 'drugSynonyms_string': 'Vernakalant', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCND3 (ENSG00000171385), KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_718', 'drugName': 'Vernakalant', 'tradeNames_string': '', 'drugSynonyms_string': 'Vernakalant', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCND3 (ENSG00000171385), KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_715', 'drugName': 'Vernakalant', 'tradeNames_string': '', 'drugSynonyms_string': 'Vernakalant', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCND3 (ENSG00000171385), KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_717', 'drugName': 'Vernakalant', 'tradeNames_string': '', 'drugSynonyms_string': 'Vernakalant', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCND3 (ENSG00000171385), KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_719', 'drugName': 'Vernakalant', 'tradeNames_string': '', 'drugSynonyms_string': 'Vernakalant', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCND3 (ENSG00000171385), KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1590', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1586', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1587', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1589', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1588', 'drugName': 'Vernakalant Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Brinavess, Kynapid, RSD-1235, RSD1235, Vernakalant hcl, Vernakalant hydrochloride', 'linkedDiseasesDrug_string': 'Atrial Flutter (EFO_0003911), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNA5 (ENSG00000130037), KCNJ3 (ENSG00000162989), KCNJ5 (ENSG00000120457), KCNH2 (ENSG00000055118), SCN5A (ENSG00000183873), KCND3 (ENSG00000171385)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.714 | Q17 | What gene does the drug Interferon Gamma-1B target? | The drug Interferon Gamma-1B targets 2 genes: IFNGR1 and IFNGR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon gamma-1b%" OR LOWER(tradeNames_string) LIKE "%interferon gamma-1b%" OR LOWER(drugSynonyms_string) LIKE "%interferon gamma-1b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3679', 'drugName': 'Interferon Gamma-1B', 'tradeNames_string': 'Actimmune, Immukin', 'drugSynonyms_string': 'Ifn-.gamma., Ifn-.gamma.1b, Imifn, Immune ifn, Interferon .gamma.-1b, Interferon gama-1b, Interferon gamma, Interferon gamma-1b, Interferon gamma-1b, recombinant, Interferon gamma-1b,recomb., Interferon gamma-2a, Interferon-.gamma., Interferon-.gamma. (human)', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Friedreich Ataxia (MONDO_0100339), Cryptococcal Meningitis (EFO_0007228), Retinal Degeneration (MONDO_0004580), Anogenital Venereal Wart (EFO_0007147), Idiopathic Pulmonary Fibrosis (EFO_0000768), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Uveitis (EFO_1001231), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Chronic Granulomatous Disease (MONDO_0018305), Anterior Uveitis (EFO_1000811), Rhabdomyosarcoma (EFO_0002918), Mycobacterium Infection (EFO_0009429), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Chronic Hepatitis C Virus Infection (EFO_0004220), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Cutaneous Melanoma (EFO_0000389), Mycobacterium Avium Complex Disease (EFO_0007386), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Reactive Arthritis (EFO_0007460), Neoplasm (EFO_0000616), Ewing Sarcoma (EFO_0000174), Leukocyte-Adhesion Deficiency Syndrome (EFO_1001359), Hiv Infection (EFO_0000764), Leukemia (EFO_0000565), Xerostomia (EFO_0009869), Prostatitis (EFO_0003830), Melanoma (EFO_0000756), Cystic Fibrosis (MONDO_0009061), Candidemia (EFO_1001282), Pulmonary Fibrosis (EFO_0009448), Osteopetrosis (MONDO_0017198), Cirrhosis Of Liver (EFO_0001422), Albers-Schönberg Osteopetrosis (Orphanet_53)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNGR2 (ENSG00000159128), IFNGR1 (ENSG00000027697)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1335 | Q17 | What gene does the drug Ticlopidine Hydrochloride target? | The drug Ticlopidine Hydrochloride targets the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ticlopidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ticlopidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ticlopidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1201', 'drugName': 'Ticlopidine Hydrochloride', 'tradeNames_string': 'Ticlid, Ticlopidine hydrochloride, Tiklid', 'drugSynonyms_string': '4-C-32, 53-32C, Ipaton, NSC-759165, Ticlopidine hcl, Ticlopidine hydrochloride', 'linkedDiseasesDrug_string': 'Thrombotic Disease (MONDO_0000831), Stroke (EFO_0000712)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1156 | Q17 | What gene does the drug Abt-102 target? | The drug Abt-102 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TRPV1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abt-102%" OR LOWER(tradeNames_string) LIKE "%abt-102%" OR LOWER(drugSynonyms_string) LIKE "%abt-102%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3254', 'drugName': 'Abt-102', 'tradeNames_string': '', 'drugSynonyms_string': 'ABT-102, Abt-102', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRPV1 (ENSG00000196689)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.338 | Q17 | What gene does the drug Tazemetostat target? | The drug Tazemetostat targets the gene EZH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tazemetostat%" OR LOWER(tradeNames_string) LIKE "%tazemetostat%" OR LOWER(drugSynonyms_string) LIKE "%tazemetostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1211', 'drugName': 'Tazemetostat', 'tradeNames_string': '', 'drugSynonyms_string': 'E-7438, E7438, EPZ-6438, EPZ6438, Tazemetostat', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Follicular Lymphoma (MONDO_0018906), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Mesothelioma (EFO_0000588), Lymphoma (EFO_0000574), Sarcoma (EFO_0000691), Urothelial Carcinoma (EFO_0008528), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Epithelioid Sarcoma (MONDO_0017387)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EZH2 (ENSG00000106462)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4960', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_string': 'Tazverik', 'drugSynonyms_string': 'E-7438 HYDROBROMIDE, EPZ-6438 HYDROBROMIDE, EPZ-6438 MONOHYDROBROMIDE, EZ-438, EZ438, Tazemetostat hydrobromide, Tazemetostat monohydrobromide', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Small Cell Lung Carcinoma (EFO_0000702), Sarcoma (EFO_0000691)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EZH2 (ENSG00000106462)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1343 | Q17 | What gene does the drug Ocriplasmin target? | The drug Ocriplasmin targets 38 genes: LAMA1, LAMA3, LAMB4, COL2A1, LAMA4, LAMC1, COL28A1, COL6A2, COL18A1, COL11A2, COL4A1, COL6A6, COL15A1, COL4A5, LAMC3, LAMB3, COL5A3, COL6A3, COL4A3, COL24A1, COL4A6, COL4A4, COL1A1, LAMB1, LAMC2, COL4A2, COL6A5, COL27A1, COL11A1, FN1, COL1A2, COL3A1, COL5A1, LAMA2, LAMA5, COL6A1, COL5A2 and LAMB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ocriplasmin%" OR LOWER(tradeNames_string) LIKE "%ocriplasmin%" OR LOWER(drugSynonyms_string) LIKE "%ocriplasmin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5818', 'drugName': 'Ocriplasmin', 'tradeNames_string': '', 'drugSynonyms_string': 'Jetrea, MICROPLASMIN, Microplasmin (synthetic human), Ocriplasmin, Plasmin, micro- (synthetic human), Recombinant human microplasmin', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Macular Degeneration (EFO_0009606), Retinal Vein Occlusion (EFO_1001157), Stroke (EFO_0000712), Eye Disease (EFO_0003966), Deep Vein Thrombosis (EFO_0003907), Macular Holes (EFO_1001028)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'numberLinkedTargets': 38}, {'UUID': 'DrugGeneTargets_v2_5819', 'drugName': 'Ocriplasmin', 'tradeNames_string': '', 'drugSynonyms_string': 'Jetrea, MICROPLASMIN, Microplasmin (synthetic human), Ocriplasmin, Plasmin, micro- (synthetic human), Recombinant human microplasmin', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Macular Degeneration (EFO_0009606), Retinal Vein Occlusion (EFO_1001157), Stroke (EFO_0000712), Eye Disease (EFO_0003966), Deep Vein Thrombosis (EFO_0003907), Macular Holes (EFO_1001028)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'numberLinkedTargets': 38}, {'UUID': 'DrugGeneTargets_v2_5820', 'drugName': 'Ocriplasmin', 'tradeNames_string': '', 'drugSynonyms_string': 'Jetrea, MICROPLASMIN, Microplasmin (synthetic human), Ocriplasmin, Plasmin, micro- (synthetic human), Recombinant human microplasmin', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Macular Degeneration (EFO_0009606), Retinal Vein Occlusion (EFO_1001157), Stroke (EFO_0000712), Eye Disease (EFO_0003966), Deep Vein Thrombosis (EFO_0003907), Macular Holes (EFO_1001028)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FN1 (ENSG00000115414), COL1A2 (ENSG00000164692), COL1A1 (ENSG00000108821), COL2A1 (ENSG00000139219), COL3A1 (ENSG00000168542), COL4A1 (ENSG00000187498), COL5A1 (ENSG00000130635), COL6A1 (ENSG00000142156), COL11A1 (ENSG00000060718), COL15A1 (ENSG00000204291), COL18A1 (ENSG00000182871), COL24A1 (ENSG00000171502), COL27A1 (ENSG00000196739), COL28A1 (ENSG00000215018), COL4A2 (ENSG00000134871), COL5A2 (ENSG00000204262), COL6A2 (ENSG00000142173), COL11A2 (ENSG00000204248), COL4A3 (ENSG00000169031), COL5A3 (ENSG00000080573), COL6A3 (ENSG00000163359), COL4A4 (ENSG00000081052), COL4A5 (ENSG00000188153), COL6A5 (ENSG00000172752), COL4A6 (ENSG00000197565), COL6A6 (ENSG00000206384), LAMA1 (ENSG00000101680), LAMA2 (ENSG00000196569), LAMA3 (ENSG00000053747), LAMA4 (ENSG00000112769), LAMA5 (ENSG00000130702), LAMB1 (ENSG00000091136), LAMB2 (ENSG00000172037), LAMB3 (ENSG00000196878), LAMB4 (ENSG00000091128), LAMC1 (ENSG00000135862), LAMC2 (ENSG00000058085), LAMC3 (ENSG00000050555)', 'numberLinkedTargets': 38}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1593 | Q17 | What gene does the drug Masupirdine target? | The drug Masupirdine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%masupirdine%" OR LOWER(tradeNames_string) LIKE "%masupirdine%" OR LOWER(drugSynonyms_string) LIKE "%masupirdine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4255', 'drugName': 'Masupirdine', 'tradeNames_string': '', 'drugSynonyms_string': 'Masupirdine, SUVN-502, Suvn-502', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR6 (ENSG00000158748)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1993 | Q17 | What gene does the drug Dopamine Hydrochloride target? | The drug Dopamine Hydrochloride targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dopamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dopamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dopamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4778', 'drugName': 'Dopamine Hydrochloride', 'tradeNames_string': 'Dopamin-Natterman, Dopamine hydrochloride, Dopmin, Dynatra, Intropin, Sabax Dopamin, Selectajet', 'drugSynonyms_string': 'ASL-279, Cardiosteril, Dopamine hcl, Dopamine hydrochloride, Dopamini hydrochloridum, Inotropin, NSC-169105, Tensamin', 'linkedDiseasesDrug_string': 'Kidney Failure (EFO_1002048), Congestive Heart Failure (EFO_0000373), Myocardial Infarction (EFO_0000612), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.598 | Q17 | What gene does the drug Alisertib target? | The drug Alisertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene AURKA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alisertib%" OR LOWER(tradeNames_string) LIKE "%alisertib%" OR LOWER(drugSynonyms_string) LIKE "%alisertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1576', 'drugName': 'Alisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'Alisertib, MLN 8237, MLN-8237, MLN8237, Mln-8237', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Neuroblastoma (EFO_0000621), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Digestive System Cancer (MONDO_0002516), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Peritoneum Cancer (MONDO_0002087), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKA (ENSG00000087586)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.16 | Q17 | What gene does the drug Afatinib target? | The drug Afatinib targets 3 genes: ERBB2, ERBB4 and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%afatinib%" OR LOWER(tradeNames_string) LIKE "%afatinib%" OR LOWER(drugSynonyms_string) LIKE "%afatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2560', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1043', 'drugName': 'Afatinib', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugSynonyms_string': 'Afatinib, BIBW-2992, BIBW2992, Bibw 2992, NSC-750691, Tomtovok, Tovok', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1042', 'drugName': 'Afatinib', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugSynonyms_string': 'Afatinib, BIBW-2992, BIBW2992, Bibw 2992, NSC-750691, Tomtovok, Tovok', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2558', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2559', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1044', 'drugName': 'Afatinib', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugSynonyms_string': 'Afatinib, BIBW-2992, BIBW2992, Bibw 2992, NSC-750691, Tomtovok, Tovok', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1855 | Q17 | What gene does the drug Ozanimod Hydrochloride target? | The drug Ozanimod Hydrochloride targets the gene S1PR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ozanimod hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ozanimod hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ozanimod hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5399', 'drugName': 'Ozanimod Hydrochloride', 'tradeNames_string': 'Zeposia', 'drugSynonyms_string': 'Ozanimod hydrochloride, RPC-1063 HCL, RPC1063 HCL', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1634 | Q17 | What gene does the drug Parecoxib Sodium target? | The drug Parecoxib Sodium targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%parecoxib sodium%" OR LOWER(tradeNames_string) LIKE "%parecoxib sodium%" OR LOWER(drugSynonyms_string) LIKE "%parecoxib sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2672', 'drugName': 'Parecoxib Sodium', 'tradeNames_string': 'Dynastat', 'drugSynonyms_string': 'Parecoxib sodium, Parecoxib sodium salt, SC-69124A', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Osteoarthritis (MONDO_0005178)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1686 | Q17 | What gene does the drug Inotuzumab target? | The drug Inotuzumab targets the gene CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inotuzumab%" OR LOWER(tradeNames_string) LIKE "%inotuzumab%" OR LOWER(drugSynonyms_string) LIKE "%inotuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6318', 'drugName': 'Inotuzumab Ozogamicin', 'tradeNames_string': 'Besponsa', 'drugSynonyms_string': 'CMC-544, Inotuzumab ozogamicin, PF-05208773, WAY-207294, WAY-207294 CMC-544', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1534', 'drugName': 'Inotuzumab', 'tradeNames_string': 'Besponsa', 'drugSynonyms_string': 'G544, Inotuzumab', 'linkedDiseasesDrug_string': 'Acute Lymphoblastic Leukemia (EFO_0000220)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.600 | Q17 | What gene does the drug Perhexiline Maleate target? | The drug Perhexiline Maleate targets 3 genes: CPT2, CPT1B and MTOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perhexiline maleate%" OR LOWER(tradeNames_string) LIKE "%perhexiline maleate%" OR LOWER(drugSynonyms_string) LIKE "%perhexiline maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1724', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1725', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1726', 'drugName': 'Perhexiline Maleate', 'tradeNames_string': 'Pexid, Pexsig', 'drugSynonyms_string': 'NSC-758409, Perhexiline maleate, Perhexilinum', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.924 | Q17 | What gene does the drug Tebentafusp target? | The drug Tebentafusp targets the gene PMEL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tebentafusp%" OR LOWER(tradeNames_string) LIKE "%tebentafusp%" OR LOWER(drugSynonyms_string) LIKE "%tebentafusp%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5977', 'drugName': 'Tebentafusp', 'tradeNames_string': 'Kimmtrak', 'drugSynonyms_string': 'IMCGP-100, IMCGP100, IMCgp 100, IMMTAC IMCGP100, Imcgp100, ImmTAC IMCgpgp 100, Kimmtrak, Tebentafusp, Tebentafusp tebn, Tebentafusp-tebn', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Uveal Cancer (EFO_1001230)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PMEL (ENSG00000185664)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.471 | Q17 | What gene does the drug Pitavastatin Sodium target? | The drug Pitavastatin Sodium targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pitavastatin sodium%" OR LOWER(tradeNames_string) LIKE "%pitavastatin sodium%" OR LOWER(drugSynonyms_string) LIKE "%pitavastatin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1489', 'drugName': 'Pitavastatin Sodium', 'tradeNames_string': 'Nikita', 'drugSynonyms_string': 'Pitavastatin sodium', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentration (HP_0003119), Familial Hypercholesterolemia (EFO_0004911), Hyperlipidemia (MONDO_0021187), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.202 | Q17 | What gene does the drug Icatibant target? | The drug Icatibant targets the gene BDKRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%icatibant%" OR LOWER(tradeNames_string) LIKE "%icatibant%" OR LOWER(drugSynonyms_string) LIKE "%icatibant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_226', 'drugName': 'Icatibant Acetate', 'tradeNames_string': 'Firazyr', 'drugSynonyms_string': 'HOE 140, HOE-140, Icatibant acetate', 'linkedDiseasesDrug_string': 'Angioedema (EFO_0005532), Hereditary Angioedema (MONDO_0019623), Inflammation (MP_0001845), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BDKRB2 (ENSG00000168398)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3024', 'drugName': 'Icatibant', 'tradeNames_string': '', 'drugSynonyms_string': 'HOE-140, Icatibant', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Covid-19 (MONDO_0100096), Angioedema (EFO_0005532), Joint Disease (EFO_1000999), Inflammation (MP_0001845), Mitochondrial Disease (MONDO_0044970), Hereditary Angioedema (MONDO_0019623), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BDKRB2 (ENSG00000168398)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1206 | Q17 | What gene does the drug Methylprednisolone Hemisuccinate target? | The drug Methylprednisolone Hemisuccinate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylprednisolone hemisuccinate%" OR LOWER(tradeNames_string) LIKE "%methylprednisolone hemisuccinate%" OR LOWER(drugSynonyms_string) LIKE "%methylprednisolone hemisuccinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_670', 'drugName': 'Methylprednisolone Hemisuccinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Methylprednisolone hemisuccinate, Methylprednisolone succinate', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Drug-Induced Liver Injury (EFO_0004228), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Glomerulonephritis (MONDO_0002462), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Endocrine System Disease (EFO_0001379), Deafness (EFO_0001063), Bacterial Pneumonia (EFO_1001272), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Psoriatic Arthritis (EFO_0003778), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acne (EFO_0003894), Acute Graft Vs. Host Disease (EFO_0004599), Epilepsy (EFO_0000474), Immune System Disease (EFO_0000540), Secondary Progressive Multiple Sclerosis (EFO_0008522), Asthma (MONDO_0004979), Chronic Progressive Multiple Sclerosis (EFO_0003840), Inflammation (MP_0001845), Anemia (MONDO_0002280), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Japanese Encephalitis (EFO_0007332), Posterior Uveitis (EFO_1001119), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1056 | Q17 | What gene does the drug Mk-0893 target? | The drug Mk-0893 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GCGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mk-0893%" OR LOWER(tradeNames_string) LIKE "%mk-0893%" OR LOWER(drugSynonyms_string) LIKE "%mk-0893%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4471', 'drugName': 'Mk-0893', 'tradeNames_string': '', 'drugSynonyms_string': 'MK-0893, Mk-0893, Mk0893', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1195 | Q17 | What gene does the drug Eltrombopag target? | The drug Eltrombopag targets the gene MPL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eltrombopag%" OR LOWER(tradeNames_string) LIKE "%eltrombopag%" OR LOWER(drugSynonyms_string) LIKE "%eltrombopag%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2769', 'drugName': 'Eltrombopag Olamine', 'tradeNames_string': 'Promacta, Promacta kit', 'drugSynonyms_string': 'Eltrombopag (as olamine), Eltrombopag compd with 2-aminoethanol (1:2), Eltrombopag olamine, SB-497115-GR', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Severe Aplastic Anemia (EFO_0006927), Chronic Hepatitis C Virus Infection (EFO_0004220), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MPL (ENSG00000117400)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1104', 'drugName': 'Eltrombopag', 'tradeNames_string': 'Revolade', 'drugSynonyms_string': 'Eltrombopag, SB497115', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Chronic Lymphocytic Leukemia (EFO_0000095), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Hemorrhage (MP_0001914), Liver Disease (EFO_0001421), Myelodysplastic Syndrome (EFO_0000198), Hepatitis C Virus Infection (EFO_0003047), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Aplastic Anemia (HP_0001915), Acute Graft Vs. Host Disease (EFO_0004599), Thrombocytopenia (HP_0001873), Anemia (Phenotype) (EFO_0004272), Severe Aplastic Anemia (EFO_0006927), Blood Platelet Disease (MONDO_0002245), Wiskott-Aldrich Syndrome (MONDO_0010518), Chronic Hepatitis C Virus Infection (EFO_0004220), Osteosarcoma (EFO_0000637), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MPL (ENSG00000117400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1300 | Q17 | What gene does the drug Gilteritinib Fumarate target? | The drug Gilteritinib Fumarate targets 2 genes: AXL and FLT3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gilteritinib fumarate%" OR LOWER(tradeNames_string) LIKE "%gilteritinib fumarate%" OR LOWER(drugSynonyms_string) LIKE "%gilteritinib fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3307', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_string': 'Xospata', 'drugSynonyms_string': 'ASP-2215 HEMIFUMARATE, ASP2215 hemifumarate, Gilteritinib fumarate, Gilteritinib hemifumarate', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), AXL (ENSG00000167601)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3308', 'drugName': 'Gilteritinib Fumarate', 'tradeNames_string': 'Xospata', 'drugSynonyms_string': 'ASP-2215 HEMIFUMARATE, ASP2215 hemifumarate, Gilteritinib fumarate, Gilteritinib hemifumarate', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), AXL (ENSG00000167601)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1276 | Q17 | What gene does the drug Lumacaftor target? | The drug Lumacaftor targets the gene CFTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumacaftor%" OR LOWER(tradeNames_string) LIKE "%lumacaftor%" OR LOWER(drugSynonyms_string) LIKE "%lumacaftor%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1147', 'drugName': 'Lumacaftor', 'tradeNames_string': '', 'drugSynonyms_string': 'Lumacaftor, VRT 826809, VRT-826809, VX 809, VX-809', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CFTR (ENSG00000001626)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1814 | Q17 | What gene does the drug Vorsetuzumab Mafodotin target? | The drug Vorsetuzumab Mafodotin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD70. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vorsetuzumab mafodotin%" OR LOWER(tradeNames_string) LIKE "%vorsetuzumab mafodotin%" OR LOWER(drugSynonyms_string) LIKE "%vorsetuzumab mafodotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4780', 'drugName': 'Vorsetuzumab Mafodotin', 'tradeNames_string': 'Sgn-75', 'drugSynonyms_string': 'SGN-75, Vorsetuzumab mafodotin', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD70 (ENSG00000125726)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1402 | Q17 | What gene does the drug Potassium Oxybate target? | The drug Potassium Oxybate targets 2 genes: GABBR2 and GABBR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%potassium oxybate%" OR LOWER(tradeNames_string) LIKE "%potassium oxybate%" OR LOWER(drugSynonyms_string) LIKE "%potassium oxybate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2573', 'drugName': 'Potassium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxybate potassium, Potassium oxybate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1807 | Q17 | What gene does the drug Isopropamide target? | The drug Isopropamide targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isopropamide%" OR LOWER(tradeNames_string) LIKE "%isopropamide%" OR LOWER(drugSynonyms_string) LIKE "%isopropamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3463', 'drugName': 'Isopropamide', 'tradeNames_string': '', 'drugSynonyms_string': 'Isopropamide, Isopropamide cation, Isopropamide ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3462', 'drugName': 'Isopropamide', 'tradeNames_string': '', 'drugSynonyms_string': 'Isopropamide, Isopropamide cation, Isopropamide ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4391', 'drugName': 'Isopropamide Iodide', 'tradeNames_string': 'Darbid', 'drugSynonyms_string': 'Dipramid, Dipramide, Isamid, Isopropamide (as iodide), Isopropamide iodide, Isoproponum iodide, Marygin-m, NSC-15521, Piaccamide, Priamide, Priazimide, SKF-4740, Sanulcin, Tyrimide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4390', 'drugName': 'Isopropamide Iodide', 'tradeNames_string': 'Darbid', 'drugSynonyms_string': 'Dipramid, Dipramide, Isamid, Isopropamide (as iodide), Isopropamide iodide, Isoproponum iodide, Marygin-m, NSC-15521, Piaccamide, Priamide, Priazimide, SKF-4740, Sanulcin, Tyrimide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.661 | Q17 | What gene does the drug Budesonide target? | The drug Budesonide targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_string) LIKE "%budesonide%" OR LOWER(drugSynonyms_string) LIKE "%budesonide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3329', 'drugName': 'Budesonide', 'tradeNames_string': 'Aircort, Budeflam aquanase, Budelin novolizer, Budenofalk, Budesonide, Cortiment, Duoresp spiromax, Entocort, Entocort cr, Entocort ec, Ortikos, Preferid, Pulmaxan, Pulmicort, Pulmicort flexhaler, Pulmicort l.s., Pulmicort respules, Rhinocort, Rhinocort allergy, Rhinocort aqua, Rhinocort aqua 64, Symbicort, Tarpeyo, Uceris', 'drugSynonyms_string': 'Budesonide, MAP-0010, MAP0010, NSC-757788, R01AD05, S-1320', 'linkedDiseasesDrug_string': "Status Asthmaticus (EFO_0008590), Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Multiple Myeloma (EFO_0001378), Esophageal Stricture (HP_0002043), Radiation Pneumonitis (EFO_1001411), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Iga Glomerulonephritis (EFO_0004194), Lymphocytic Colitis (EFO_1001294), Allergic Rhinitis (EFO_0005854), Ulcerative Colitis (EFO_0000729), Primary Biliary Cirrhosis (EFO_1001486), Bronchiolitis Obliterans (EFO_0007183), Proctitis (EFO_0005628), Diarrhea (HP_0002014), Collagenous Colitis (EFO_1001293), Crohn'S Disease (EFO_0000384), Breast Cancer (MONDO_0007254), Seasonal Allergic Rhinitis (EFO_0003956), Acute Respiratory Distress Syndrome (EFO_1000637), Acute Graft Vs. Host Disease (EFO_0004599), Emphysema (EFO_0000464), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Respiratory System Disease (EFO_0000684), Ulcerative Proctosigmoiditis (EFO_1001223), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Obstructive Sleep Apnea (EFO_0003918), Nasal Congestion (HP_0001742), Malnutrition (EFO_0008572), Altitude Sickness (EFO_1000782), Allergic Disease (MONDO_0005271), Microscopic Colitis (EFO_1001295), Sclerosing Cholangitis (EFO_0004268), Chronic Bronchitis (EFO_0006505), Lung Cancer (MONDO_0008903), Autoimmune Hepatitis (EFO_0005676), Melanoma (EFO_0000756), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694), Snoring (HP_0025267)", 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.560 | Q17 | What gene does the drug Pl-3994 target? | The drug Pl-3994 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NPR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pl-3994%" OR LOWER(tradeNames_string) LIKE "%pl-3994%" OR LOWER(drugSynonyms_string) LIKE "%pl-3994%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_478', 'drugName': 'Pl-3994', 'tradeNames_string': '', 'drugSynonyms_string': 'Pl-3994', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'NPR1 (ENSG00000169418)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.44 | Q17 | What gene does the drug Phenylephrine Hydrochloride target? | The drug Phenylephrine Hydrochloride targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phenylephrine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phenylephrine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3941', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_string': 'Afrin 4 hour nasal spray, Biomydrin, Biorphen, Fenilfar, Fenox, Mydfrin, Nazex, Neo-synephrine, Neosynephrine, Nostril, Nurofen sinus pain relief, Phenylephrine hydrochloride, Prefrin, Vazculep', 'drugSynonyms_string': 'Metaoxedrine chloride, NSC-757273, Phenylephrine HCl, Phenylephrine hydrochloride', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Acute Lung Injury (EFO_0004610), Infection (EFO_0000544), Hypotension (EFO_0005251), Septic Shock (EFO_0006834), Seasonal Allergic Rhinitis (EFO_0003956), Hemorrhoid (EFO_0009552), Cataract (MONDO_0005129), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Vasomotor Rhinitis (EFO_0007533), Respiratory Tract Infectious Disorder (MONDO_0024355), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271), Gastric Carcinoma (EFO_0000178), Pruritus (HP_0000989), Rhinitis (EFO_0008521)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.278 | Q17 | What gene does the drug Avanafil target? | The drug Avanafil targets the gene PDE5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%avanafil%" OR LOWER(tradeNames_string) LIKE "%avanafil%" OR LOWER(drugSynonyms_string) LIKE "%avanafil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5497', 'drugName': 'Avanafil', 'tradeNames_string': 'Spedra, Stendra', 'drugSynonyms_string': 'Avanafil, TA-1790', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Erectile Dysfunction (EFO_0004234)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1096 | Q17 | What gene does the drug Navafenterol target? | The drug Navafenterol is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRM3 and ADRB2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%navafenterol%" OR LOWER(tradeNames_string) LIKE "%navafenterol%" OR LOWER(drugSynonyms_string) LIKE "%navafenterol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6388', 'drugName': 'Navafenterol', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-8871, AZD8871, Azd 8871, Azd-8871, Azd8871, LAS-191351, LAS191351, Navafenterol', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6389', 'drugName': 'Navafenterol', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-8871, AZD8871, Azd 8871, Azd-8871, Azd8871, LAS-191351, LAS191351, Navafenterol', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.104 | Q17 | What gene does the drug Bempedoic Acid target? | The drug Bempedoic Acid targets the gene ACLY. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bempedoic acid%" OR LOWER(tradeNames_string) LIKE "%bempedoic acid%" OR LOWER(drugSynonyms_string) LIKE "%bempedoic acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5953', 'drugName': 'Bempedoic Acid', 'tradeNames_string': 'Nexletol', 'drugSynonyms_string': 'Bempedoic acid, ESP-55016, ETC-1002, ETC1002', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACLY (ENSG00000131473)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.856 | Q17 | What gene does the drug Pyrovalerone target? | The drug Pyrovalerone targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pyrovalerone%" OR LOWER(tradeNames_string) LIKE "%pyrovalerone%" OR LOWER(drugSynonyms_string) LIKE "%pyrovalerone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_225', 'drugName': 'Pyrovalerone', 'tradeNames_string': '', 'drugSynonyms_string': 'J8.659B, Pyrovalerone', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_471', 'drugName': 'Pyrovalerone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Centroton, F 1983, F-1983, Pyrovalerone hcl, Pyrovalerone hydrochloride, SP-1059, Thymergix', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.985 | Q17 | What gene does the drug Alectinib target? | The drug Alectinib targets 3 genes: EML4, ALK and RET. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alectinib%" OR LOWER(tradeNames_string) LIKE "%alectinib%" OR LOWER(drugSynonyms_string) LIKE "%alectinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1251', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'Alectinib hydrochloride', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4672', 'drugName': 'Alectinib', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'AF-802, AF802, Alectinib, CH-5424802, CH5424802, RO-5424802, RO5424802', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4671', 'drugName': 'Alectinib', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'AF-802, AF802, Alectinib, CH-5424802, CH5424802, RO-5424802, RO5424802', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1249', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'Alectinib hydrochloride', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1250', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'Alectinib hydrochloride', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4673', 'drugName': 'Alectinib', 'tradeNames_string': 'Alecensa', 'drugSynonyms_string': 'AF-802, AF802, Alectinib, CH-5424802, CH5424802, RO-5424802, RO5424802', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.948 | Q17 | What gene does the drug Linerixibat target? | The drug Linerixibat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC10A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linerixibat%" OR LOWER(tradeNames_string) LIKE "%linerixibat%" OR LOWER(drugSynonyms_string) LIKE "%linerixibat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1185', 'drugName': 'Linerixibat', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK2330672, Gsk-2330672, Gsk2330672, Linerixibat', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Pruritus (HP_0000989), Cholestasis (MONDO_0001751), Intrahepatic Cholestasis (MONDO_0019072)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC10A2 (ENSG00000125255)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.